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1. Introduction
A large outbreak of acute viral hepatitis in New Delhi in 
1955–56 (Vishwanathan 1957) was retrospectively found 
to be due to a unique agent called enteric non-A, non-B 
hepatitis. This agent was later named hepatitis E virus 
(HEV) and molecularly characterized following the cloning 
of its genome (Reyes et al 1990). Much information is 
now available on the epidemiology, virology, transmission 
and pathogenesis of HEV. A review with the same title 
was published almost a decade ago (Jameel 1999). While 
maintaining the earlier style, this review will highlight new 
developments in the fi eld since then. 
2. Epidemiology
HEV is the causative agent for hepatitis E, a major form of 
acute viral hepatitis. The disease is endemic in large parts 
of Asia, Africa and Latin America (fi gure 1) from where 
epidemic and sporadic disease has been reported (Panda 
and Jameel 1997; Jameel 1999). It is estimated that about 2 
billion people live in areas endemic for HEV.
The common feature between almost all the epidemics 
is the contamination of water supplies with sewage, 
confi rming the feco-oral route of transmission. The highest 
rates of infection occur in regions with poor sanitation and 
socio-economic status of the population. Minor modes of 
transmission in endemic areas could be vertical (Khuroo 
et al 1995) and through blood transfusions (Khuroo et al 
2004). Person-to-person contact transmission is ineffi cient 
(Somani et al 2003). 
Blood donors and healthy persons from some non-
endemic areas also show high anti-HEV prevalence (Mast 
et al 1997; Thomas et al 1997; Meng 2000a, b) (fi gure 1). 
This could be due to zoonotic transmission. Besides the 
discovery of a swine HEV (Meng et al 1997), related viruses 
have been found in pigs (Clayson et al 1995; van der Poel et 
al 2001; Arankalle et al 2002; Huang et al 2002; Pei and Yoo 
2002), deer (Tei et al 2003; van Cuyck et al 2005), and wild 
boar (Takahashi et al 2004). Direct transmission has been 
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reported from deer to humans as a result of eating uncooked 
meat (Tei et al 2003, 2004). Swine HEV was detected in 
raw pig livers (Yazaki et al 2003) and genotyping data 
indicate clustering of swine and human HEV strains from 
patients in the USA, Japan and other countries. Humans 
who consume contaminated pork products and are involved 
in the rearing of pigs are potentially at risk of HEV infection 
(Matsuda et al 2003; Tei et al 2004; Zheng et al 2006). Anti-
HEV antibodies have been detected in many more animal 
species, including wild boar and deer and HEV genotype 
3 was identifi ed from a boar in Japan (Sonoda et al 2004). 
Swine HEV in India differs genetically from human HEV, 
indicating that pigs may not play an important role in the 
spread of human hepatitis E in endemic regions (Arankalle 
et al 2002; Shukla et al 2007).
High anti-HEV prevalence is reported in rodents from 
several geographic regions (Kabrane-Lazizi et al 1999; 
Arankalle et al 2001), and a strain of HEV has been 
genetically identifi ed from wild rats (Tsarev et al 1998). 
Avian HEV was identifi ed and molecularly characterized 
from chickens with hepatitis–splenomegaly syndrome in the 
USA (Haqshenas et al 2001). Like swine HEV, avian HEV 
is also related genetically and antigenically to human HEV 
(Huang et al 2004; Feagins et al 2007).
Seroprevalence rates are higher in endemic regions 
compared to areas where HEV infection is rare. Imported 
cases of hepatitis E have been seen in non-endemic regions 
such as Australia, France, Israel, The Netherlands, Spain, 
UK and USA; occasional cases with no recent history 
of travel are also observed. Anti-HEV seroprevalance of 
~16% has been observed in southwest France; this could 
be responsible for active autochthonous transmission in this 
region (Mansuy et al 2008).
The zoonotic transmission of HEV is a serious issue 
in developed countries. Though a majority of infections 
are asymptomatic, sustained transmission can lead to the 
evolution of virulent strains in future (Ijaz et al 2005; 
Zheng et al 2006). HEV genotype 3 infections have become 
more common in the United Kingdom, like genotype 4 did 
in China in the past decade (Wang 2003; Ijaz et al 2005). 
Genotype 3 is widely distributed and evolution of virulent 
strains would have more far-reaching consequences (Zheng 
et al 2006).
3. Clinical presentation and pathogenesis
The HEV target population is young to middle aged adults, 
15 to 40 years of age. The clinical symptoms are typical of 
acute viral hepatitis and include jaundice, malaise, anorexia, 
nausea, abdominal pain, fever and hepatomegaly; anicteric 
hepatitis is also observed (Smith 2001). The disease is 
self-limiting and no chronic sequelae have been reported in 
general. However, two recent reports present biochemical, 
Figure 1. HEV endemic areas and global seroprevalence. Red areas on the map indicate regions of the world that are endemic for 
hepatitis E and where >25% of acute viral hepatitis is due to HEV. Superimposed on this map are seroprevalence rates of HEV from various 
countries, determined in independent studies.
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histological and genetic evidence of chronic HEV infection in 
transplant patients (Haagsma et al 2008; Kamar et al 2008). 
It would be interesting to test other immunosuppressed 
persons, such as those with HIV infection, for their ability to 
resolve acute hepatitis E.
Hepatitis E has a mortality rate of 0.2–1% in the general 
population. Increased morbidity and mortality is observed 
in chronic liver disease patients superinfected with HEV 
(Hamid et al 2002). A unique clinical feature is its increased 
incidence and severity in pregnant women, with mortality 
rates of 15–20% (Khuroo et al 1981). A role or endotoxin-
mediated hepatocyte injury was proposed (Purcell and 
Ticehurst 1997; Jameel 1999), but the precise cellular/
molecular mechanisms are not clear. A shift in the Th1/Th2 
balance towards Th2 has been observed in pregnant women 
infected with HEV compared to non-pregnant women (Pal 
et al 2005), but how this infl uences the severity of HEV 
infection is not clear. Pregnant women with jaundice and 
acute viral hepatitis due to HEV showed higher mortality 
rates and worse obstetric and fetal outcomes than those 
with other types of viral hepatitis (Patra et al 2007). There 
were increased levels of estrogen, progesterone and βHCG 
in HEV-positive pregnant patients with fulminant hepatitis 
compared to HEV-negative patients and controls (Jilani 
et al 2007). Selective suppression of nuclear factor kappa 
B (NFκB) p65 in pregnant compared to non-pregnant 
fulminant hepatitis patients has also been proposed to cause 
liver degeneration, severe immunodefi ciency and multi-
organ failure (Prusty et al 2007).
4. Classifi cation and Phylogeny
The International Committee for Taxonomy of Viruses has 
classifi ed HEV as a Hepevirus in the family Hepeviridae 
(http://www.ncbi.nlm.nih.gov/8threportICTV/).
The HEV genomes of several geographically distinct 
isolates show a high degree of sequence conservation 
(Arankalle et al 1999). At least four phylogenetically 
distinct genotypes have been defi ned, which distribute by 
geographic regions (fi gure 2). Genotype 1 includes Asian 
and African HEV strains, genotype 2 includes the single 
Mexican HEV strain and few variants identifi ed from 
endemic cases in African countries, genotype 3 includes 
human and swine HEV strains from industrialized countries, 
and genotype 4 includes human and swine HEV strains from 
Asia, particularly China, Taiwan and Japan. The avian HEV 
was proposed to belong to a new genotype 5 (Haqshenas 
et al 2001; Huang et al 2004), but this has not yet been 
confi rmed.
A HEV genotype is dominant in a given geographic area, 
but not limited to it. For example, genotype 2 fi rst identifi ed 
in Mexico (Huang et al 1992) was later found on the African 
continent (Buisson et al 2000; Maila et al 2004; Nicand 
et al 2005). Recently, HEV genotype 1 was observed in 
Cuba in the Americas (Montalvo et al 2008). Swine HEV 
isolates belong to either genotype 3 or 4 (Hsieh et al 1999; 
Okamoto et al 2001; van der Poel et al 2001; Huang et al 
2002; Takahashi et al 2003; Meng 2005; Feagins et al 2007), 
but recently genotype 1 was detected in a pig in Cambodia 
(Caron et al 2006).
Though there is inter- and intra-patient diversity of HEV, 
its relevance to viral pathogenesis is not clear (Grandadam 
et al 2004). All HEV genotypes show varying degrees 
of intra-genome diversity (Okamoto 2007). Some recent 
reports indicate an effect of genotype on viral transmission 
and disease severity. Outbreaks due to HEV genotype 1 
and 2 are the result of effi cient human-to-human feco-oral 
transmission. HEV strains of genotype 3 and 4 are maintained 
among animal species and occasionally infect humans 
probably due to ineffi cient cross-species transmission. This 
is supported by the recovery of HEV isolate HE-JA4 from a 
patient who was infected after ingestion of undercooked pig 
liver; the sequence was identical to the swine HEV isolate 
swJL145 (Okamoto 2007). Genotype 4 was recently shown 
to cause more severe disease than genotype 3 (Mizuo et al 
2005), and higher viral loads were observed for genotype 4 
in a co-infected patient (Takahashi et al 2002).
5. Molecular virology
5.1 Animal models and in vitro culture
HEV transmission studies have mostly been done in non-
human primates such as cynomolgus, rhesus and owl 
monkeys, and chimpanzees (Uchida et al 1991; Ticehurst et 
al 1992; Vitral et al 1998; McCaustland et al 2000). These 
have provided important information regarding the biology 
and pathogenesis of HEV, and are indispensable tools for 
vaccine and drug testing (Kamili et al 2004; Purcell et al 
2003). Experimental transmission studies have also been 
done in pigs, an established reservoir for HEV (Williams et 
al 2001).
There has been only limited success in generating 
suitable tissue culture replication systems for HEV. Early 
studies reported propagation of HEV in 2BS (Huang et 
al 1992), A549 (Huang et al 1995; Wei et al 2000) and 
FRhK (Kazachkov et al 1992) cells. Infection of primary 
cynomolgus hepatocytes and PLC/PRF/5 cells has been 
shown, but replication was ineffi cient (Tam et al 1996; 
Meng et al 1997). Recently, HEV genotype 3 from a high 
titer stool suspension was successfully passaged for multiple 
generations in PLC/PRF/5 cells (Tanaka et al 2007) and 
these cells were used to assess the infectivity of HEV shed 
in patients’ stools (Takahashi et al 2007). The replication 
of HEV has been observed in cell lines transfected with 
transcripts of infectious cDNA clones and with a replicon 
derived from it (Panda et al 2000; Emerson et al 2004). 
Monkeys inoculated with culture media or lysates of HEV 
replicon-transfected cells developed infection, but viral 
titers were low. Some species barrier for HEV replication 
might exist since replicons did not function in non-primate 
cell lines. 
5.2 Genome organization
HEV is a spherical, non-enveloped virus of about 27–34 nm 
(Krawczynski et al 2000) (fi gure 2). The viral genome is a 
single-stranded, positive-sense 5′-capped RNA of ~7.2 kb. 
It consists of short 5′ and 3′ untranslated regions (UTRs), 
and three partially overlapping open reading frames (ORF), 
called ORF1, ORF2 and ORF3 (Tam et al 1991) (fi gure 3). 
The expression kinetics of the viral proteins is not clear, but 
their expression during infection is confi rmed by presence 
of antibodies in infected humans and experimental animals 
(Khudyakov et al 1994; Panda et al 1995). The UTRs and 
a conserved 58-nucleotide region within ORF1 (fi gure 3A) 
are likely to fold into conserved stem-loop and hairpin 
structures (Tam et al 1996), and together with an alphavirus 
junction homologous sequence (fi gure 3A), are postulated 
to be important for HEV RNA replication (Purdy et al 
1993). Earlier results from experimentally infected monkeys 
suggested the generation of two subgenomic RNAs (Tam et 
al 1996) but this has now been questioned. Graff et al (2006) 
recently proposed that the ORF2 and ORF3 proteins are 
translated from closely spaced AUG codons on a bicistronic 
subgenomic RNA. While this rationalizes the reading frame 
differences observed in HEV genotype 4, it remains to be 
confi rmed in an experimental model. 
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Figure 2. HEV and its genotypes. Electron micrograph showing HEV particles from the stool of a hepatitis E patient visualized after 
aggregation with anti-HEV positive serum and negative staining. A phylogenetic tree showing the distribution of human and swine HEV 
isolates in four distinct genotypes number 1 to 4 and an outlier group containing avian HEV.
5.3 HEV proteins
5.3.1 The ORF1 protein: The ORF1 of HEV encodes a 
large nonstructural protein with several putative functional 
motifs and domains such as methyltransferase, papain-like 
cysteine protease (PCP), RNA helicase and RNA dependent 
RNA polymerase (RdRp) (fi gure 3B). In vitro expression of 
the HEV ORF1 produced a polyprotein (Ansari et al 2000; 
Ropp et al 2000) that was processed into two products 
following extended incubation (Ropp et al 2000). When 
expressed in insect cells, ORF1 was processed and this 
was partially blocked by a cell permeable cysteine protease 
inhibitor (Sehgal et al 2006), but the viral or cellular 
nature of the protease remained unclear. The presence of 
methyltransferase motifs in ORF1 suggested HEV to have 
a capped RNA genome. A 5′-methylguanosine residue in the 
HEV genome was shown to be essential for infectivity and 
replication (Emerson et al 2001, 2004; Zhang et al 2001). 
The GDD motif in RdRp was reported to be important for 
HEV replication (Agrawal et al 2001; Emerson et al 2001). 
Two predicted stem-loop (SL) structures at the 3′ NCR and 
the polyA tract were necessary for RdRp binding during 
HEV genome replication (Agrawal et al 2001; Emerson et 
al 2001). Except for the methyltransferase (Magden et al 
2001), none of the other putative components of ORF1 have 
been expressed, purifi ed and biochemically characterized. 
5.3.2 The ORF2 protein: The ORF2 of HEV encodes its 
capsid protein (pORF2) of 660 amino acids and is proposed 
to encapsidate the viral RNA genome (Purdy et al 1993). 
The ORF2 protein enters the endoplasmic reticulum (ER) 
(Zafrullah et al 1999), but a fraction retrotranslocates to the 
cytoplasm to trigger a stress pathway (Surjit et al 2007). 
Replicon-based expression of pORF2 recently confi rmed 
its N-linked glycosylation (Graff et al 2008) (fi gure 3B). 
Mutations in the pORF2 glycosylation sites prevented the 
formation of infectious virus particles and had low infectivity 
in macaques (Graff et al 2008). In insect cells recombinant 
pORF2 expressed as a 56 kDa protein that lacked 111 N-
terminal and 53 C-terminal residues, and self-assembled into 
virus-like particles (VLPs) (Robinson et al 1998).
The structure of a self-assembled VLP was solved by 
cryo-electron microscopy and showed the capsid to be 
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Figure 3. Genome organization and proteins of HEV. (A) The ~7.2 kb positive strand RNA genome of HEV is capped at the 5′ end and 
polyadenylated at the 3′ end. It contains short stretches of untranslated regions (UTR) at both ends (red box). Other structural features 
proposed to be important for replication are also indicated. (B) The three open reading frames (ORFs) are shown. ORF1 encodes the 
nonstructural polyprotein (nsp) that contains various functional units – methyltransferase (MeT), papain-like cysteine protease (PCP), RNA 
helicase (Hel) and RNA dependent RNA polymerase (RdRp). ORF2 encodes the viral capsid protein; the N-terminal signal sequence (blue 
box) and glycosylation sites are indicated. ORF3 encodes a small regulatory phosphoprotein. Details of the ORF3 proteins are shown, 
including two N-terminal hydrophobic domains (blue boxes) and two C-terminal proline-rich regions (red boxes). Functions discovered for 
these domains are indicated below the illustration.
Vivek Chandra et al456
J. Biosci. 33(4), November 2008
dominated by dimers (Xing et al 1999). Self-association and 
homo-dimerization of pORF2 has been also demonstrated 
through yeast two-hybrid analysis (Tyagi et al 2001). The 
ORF2 protein also bound the 76-nucleotide (nt) region at 
the 5′ end of the HEV genome in agreement of its capsid 
encapsidation function. The RNA binding activity of pORF2 
was lost when deletions were made beyond the N-terminal 
111 amino acids (Surjit et al 2004). 
The size of the ORF2 protein in the virus particle and its 
glycosylation status are issues that are not clear. Whether 
this protein has any nonstructural functions as well is also 
not understood at this time.
5.3.3 The ORF3 protein: The ORF3 of HEV encodes a 
small protein (pORF3) of 123 amino acids. Recently it was 
proposed to be translated from a bicistronic subgenomic RNA 
and to be 9 amino acids shorter at its N-terminus (Graff et al 
2006). While ORF3 was dispensable for replication in vitro 
(Emerson et al 2006), it is required for infection in monkeys 
inoculated with HEV genomic RNA (Graff et al 2005).
Expression of pORF3 in mammalian cells showed it to 
interact with various cellular proteins. Through domain 1 
(fi gure 3B) it colocalized with the cytoskeleton (Zafrullah et 
al 1997) and bound a MAP kinase phosphatase (Kar-Roy et 
al 2004). Domain 2 was responsible for its interaction with 
hemopexin, an acute-phase plasma glycoprotein (Ratra et 
al 2008). The P1 region contains the phosphorylated serine 
residue that is conserved in all HEV strains except the 
Mexican isolate and the P2 region contains a PxxPxxP motif 
that binds several proteins containing src-homology 3 (SH3) 
domains (Korkaya et al 2001).
The ORF3 protein is likely to regulate the host cell 
environment through its interaction with various intracellular 
pathways (fi gure 4). It activates the extracellularly regulated 
kinase (ERK) by binding and inhibiting its cognate 
phosphatase (Kar-Roy et al 2004). Prolonged activation 
of ERK would generate a survival and proliferative signal 
(fi gure 4A). Higher levels of hexokinase and oligomeric 
voltage-dependent anion channel (VDAC) were found 
in ORF3-expressing cells, which displayed attenuated 
mitochondrial death signalling (Moin et al 2007) (fi gure 
4A). The ORF3 protein might act as an adaptor to link 
intracellular transduction pathways (Pawson 1995), and this 
might promote HEV replication and assembly.
We recently found that pORF3 localized to early and 
recycling endosomes, and delayed post-internalization 
traffi cking of epidermal growth factor receptor (EGFR). This 
is likely to prolong endomembrane signalling and promote 
cell survival (Chandra et al 2008) (fi gure 4B). Another 
effect of this is reduced nuclear translocation of pSTAT3 
and attenuation of the acute phase response (Chandra et al 
2008). Thus, pORF3 might reduce the host infl ammatory 
response, further creating an environment favourable for 
viral replication (fi gure 4B).
The alpha-1-microglobulin and bikunin precursor 
protein (AMBP) and its constituents α1-microglobulin and 
bikunin were also identifi ed as pORF3 binding partners 
(Tyagi et al 2004; 2005). There was increased secretion of 
α1-microglobulin from ORF3-expressing cells (Surjit et al 
2006). Since α1-microglobulin is immunosuppressive, this 
is proposed to protect virus-infected cells (fi gure 4C).
Two broad roles are thus predicted for pORF3 in HEV 
pathogenesis (fi gure 4). The fi rst is promotion of cell survival 
through ERK activation, prolonged endomembrane signaling 
and attenuation of the intrinsic death pathway (fi gure 4A, B). 
The second is to downregulate innate host responses through 
reduced expression of acute phase proteins and increased 
secretion of α1-microglobulin (fi gure 4C). 
5.4 The HEV replication cycle
5.4.1 Viral receptor and entry: Little is known about the 
cellular receptors for HEV or its entry process. A recent 
study showed that a truncated peptide p239 spanning aa 
368-606 of pORF2 formed 23 nm particles that bind and 
penetrate HepG2, Huh-7, PLC/PRF5 and A549 cells (He et 
al 2008) and prevent further infection of these cells. The cell 
surface molecules that bind HEV or its capsid protein are 
not known.
5.4.2 Model of HEV replication: A model for HEV replication 
and gene expression was proposed based on similarities and 
sequence homology to better characterized positive strand 
RNA viruses (Reyes et al 1993; Jameel 1999). This is 
shown in fi gure 5. Following entry into a permissive cell 
(step 1), the viral genomic RNA is uncoated (step 2) and 
translated in the cytosol of infected cells to produce the 
ORF1-encoded nonstructural polyprotein (nsP) (step 3). 
Cleavage of the ORF1 nsP is achieved by cellular proteases, 
possibly with help from the viral PCP. The viral replicase 
(RdRP) replicates the genomic positive strand into the 
negative strand replicative intermediates (step 4A). These 
serve as template for the synthesis of additional copies of 
the genomic positive strands as well as subgenomic positive 
strands (step 4B). This is akin to alphaviruses and a region 
homologous to alphavirus junction sequences is proposed 
to serve as the subgenomic promoter. The subgenomic 
RNA can then be translated into the structural protein(s) 
(step 5). The capsid proteins package the viral genome to 
assemble progeny virions (step 6) that exit the cell through 
an undefi ned pathway. Direct experimental confi rmation of 
this replication scheme is still awaited but several fi ndings 
increase our belief in this model. ln experimentally infected 
rhesus monkeys (Nanda et al 1994) and pigs (Meng et 
al 1998), HEV positive and negative strand RNAs are 
observed in the liver. Since in vitro transcripts of full-length 
cDNA clones are infectious for nonhuman primates and 
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pigs, the subgenomic RNAs are not required to initiate an 
infection, and must be synthesized as part of the replication 
process. Replicons have shown mixed results with respect 
to detection of negative-stranded replicative intermediates 
(Panda et al 2000; Emerson et al 2004).
6. Host immune response, detection and prophylaxis 
of hepatitis E
Studies on experimentally infected macaques fi rst defi ned 
the clinical and serological course of HEV infection. In 
those studies, serum anti-HEV immunoglobulin G (IgG) 
appeared around 3-4 weeks post-inoculation at the peak of 
ALT elevation. A human volunteer study showed anti-HEV 
IgM to peak in the symptomatic period and then decline 
to baseline within 3-6 months of illness. Serum anti-HEV 
IgG levels continued to rise during the symptomatic phase 
and were detectable in the convalescent phase for 2 years. 
In other studies anti-HEV IgG persisted for up to 13 years. 
These have been reviewed earlier (Jameel 1999; Mushahwar 
2008).
Cellular immune responses to acute HEV infection are 
poorly characterized. Srivastava et al (2007) observed 
expansion of CD4+ cells in patients compared to controls. 
However, the proportions of CD4+/CD69+ and CD8+/
CD69+ cells producing interferon gamma (IFNγ), tumour 
necrosis factor alpha (TNFα) and interleukin-4 (IL-4) 
remained unchanged following in vitro stimulation with 
Figure 4.  Role of the ORF3 protein in HEV pathogenesis. Published data show three broad functions for the ORF3 protein. (A) Promotion 
of cell survival. The ORF3 protein activates MAP kinase by binding and inactivating its cognate phosphatase (MKP). Additionally, it 
upregulates and promotes homo-oligomerization of the outer mitochondrial membrane porin, VDAC, and increases hexokinase levels, thus 
reducing mitochondrial depolarization and inhibiting intrinsic cell death. (B) Modulation of the acute phase response. The ORF3 protein 
localizes to early and recycling endosomes, and inhibits the movement of activated growth factor receptors to late endosomes. This prolongs 
endomembrane growth factor signaling and contributes to cell survival. Through this mechanism, pORF3 also reduces the nuclear transport 
of pSTAT3, a critical transcription factor for the expression of acute phase response genes. (C) Immunosuppression. The ORF3 protein 
promotes the secretion of α1-microglobulin, an immunosuppressive protein that could act in the immediate vicinity of the infected cell.
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pORF2. A decrease in IFNγ and TNFα producing T cells 
in hepatitis E patients following polyclonal activation with 
PMA and ionomycin suggested an inherent T cell activation 
defect in HEV-infected individuals. The limited immune 
reactivity observed in the peripheral compartment may 
also result from the migration and sequestration of immune 
cells to the liver. Aggarwal et al (2007) characterized 
proliferative responses from patients and controls using 
overlapping ORF2 and ORF3 peptides. The mononuclear 
cells from patients showed increased proliferation compared 
to controls, with peptide pools corresponding to amino acids 
73-156, 289-372, 361-444 and 505-588 of the ORF2 protein 
associated with signifi cant proliferation. The lymphocyte 
proliferation with ORF2 peptide pool 289-372 was found to 
be associated with the presence of HLA-DRB1 allele 010X. 
The detection of HEV infection is based on serological and 
nucleic acid tests. The former detect serum antibodies against 
HEV and the latter detect (and quantitate) HEV RNA in 
serum, bile and/or feces. Early tests for anti-HEV antibodies 
developed in various laboratories using synthetic peptides 
or recombinant proteins were employed in seroprevalence 
studies, and showed a wide variation in sensitivity (Mast et 
al 1998). Commercial IgG or IgM anti-HEV tests are now 
available from Genelabs Diagnostics, Singapore and Abbott 
Labs, Germany. An acute HEV infection is generally positive 
for both IgM and IgG anti-HEV, while only the latter is 
positive for past infection. Thus, in an endemic area, the IgM 
anti-HEV test is of value in deciding acute infection while the 
IgG test has more value in seroprevalence studies. Recently an 
ELISA for detecting putative neutralizing antibody responses 
to HEV genotypes 1 to 4 has been developed (Zhou et al 
2004), which may be useful in future trials of candidate HEV 
vaccines. Serum viremia for HEV was shown to be positive 
by reverse transcriptase polymerase chain reaction (RT-PCR) 
before ALT elevation and to last for about one week to one 
month (Chauhan et al 1993). Various in-house assays for 
HEV RNA detection based have been described (reviewed in 
Mushahwar et al 2008) that are used to confi rm an ongoing 
HEV infection. Robust, sensitive and rapid assays for HEV 
detection are required, not just for confi rming an acute HEV 
infection, but to also detect the levels of virus contamination 
in water and food. Recently, Gyarmati et al (2007) developed 
two sensitive assays to detect HEV across genotypes from 
multiple sources.
Since there is no robust system to grow HEV in culture, 
inactivated or live attenuated vaccines are not feasible. 
However, several observations suggest that recombinant 
subunit vaccines will be possible (Aggarwal and Jameel 
Figure 5.  Proposed replication cycle of HEV. The virus enters the target cell (1) and uncoats (2) to release the HEV genomic RNA through 
uncharacterized processes. The genomic RNA is translated in the cytoplasm into nonstructural proteins (3). The replicase thus synthesized 
replicates the positive strand genomic RNA into negative strand RNA intermediates (4A) and back (4B). This is the genome amplifi cation 
step. Additionally, the positive strand subgenomic RNA is also synthesized that is translated into structural proteins (5). The capsid protein 
packages the genomic RNA to assemble new virions (6) that are then released from the cell through an uncharacterized mechanism.
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2008) and are likely to protect against all four genotypes of 
HEV as they share a common serotype. A subunit vaccine 
based on a truncated ORF2 protein produced in insect cells 
using recombinant baculoviruses (Robinson et al 1998) 
showed effi cacy in a pre-clinical monkey challenge model 
(Tsarev et al 1994, 1997). This vaccine was also clinically 
tested in humans and showed ~95% effi cacy (Shrestha et 
al 2007). There is no information yet on the licensure and 
marketing of this hepatitis E vaccine. Various other hepatitis 
E vaccine candidates are in different stages of development 
and testing (reviewed in Aggarwal and Jameel 2008).
7. Old mysteries and new challenges
The earlier review (Jameel 1999) had highlighted some 
outstanding questions in hepatitis E. A decade later, it is time 
to review progress on those and highlight important issues 
for the future.
7.1 How is HEV maintained in the community during 
inter-epidemic periods?
It is quite clear now from serological and genetic studies that 
multiple animal species harbour HEV or HEV-like viruses. 
Swine HEV (Meng et al 1997) and avian HEV (Haqshenas 
et al 2001) have been genetically characterized and direct 
transmission of HEV to humans from contaminated boar 
and deer meat has been demonstrated (Tei et al 2003, 2004; 
Takahashi et al 2004). Various studies suggest that zoonotic 
transmission may be the major mode of infection in non-
endemic areas, whereas humans continue to be the major 
source of HEV in endemic areas.
7.2 How does HEV cause disease in endemic areas de-
spite patients with hepatitis E having anti-HEV antibodies?
The most logical explanation for this observation is that 
titers of anti-HEV neutralizing antibodies decline rapidly. 
As a result, while people in endemic areas still carry anti-
HEV antibodies from a previous infection, these offer no 
protection against new infection. Using the neutralizing 
antibody ELISA (Zhou et al 2004), it should now be possible 
to track anti-HEV neutralizing antibodies in persons living 
in endemic areas and to study the dynamics of this response 
following an outbreak.
7.3 What are the pathogenic mechanisms in HEV
infection?
The central epidemiological question in hepatitis E is its 
increased severity in pregnancy. There are still no concrete 
answers. Pregnant monkeys experimentally infected with 
HEV do not show this differential effect and studies in 
human patients have not adequately addressed this issue. 
Much of what we know about the potential role of HEV 
proteins in pathogenesis is based on their over-expression 
in cultured cells, which itself can be misleading. There has 
been an increased understanding of the role of pORF3 in 
HEV pathogenesis, but almost all the information is derived 
from over-expression studies. The importance of this protein 
in HEV pathogenesis is however reinforced by the lack of 
experimental infection in monkeys by an ORF3-null virus 
(Graff et al 2005).
7.4 Research on therapeutic interventions in hepatitis E
This is an ignored area of hepatitis E research. Potential 
targets on HEV include the nonstructural proteins and the 
5′ and 3′ UTRs that are critical for replication of the HEV 
genome. The nonstructural proteins are poorly characterized, 
with only the viral methyltransferase studied with any 
biochemical rigor (Magden et al 2001). Other potential 
targets are the putative papain-like cysteine protease, RNA 
helicase and replicase encoded by HEV. A report on the use 
of ribozymes to inhibit HEV RNA replication is available 
(Sriram et al 2003). A logical approach would be to focus 
on biochemical and structural characterization of the HEV 
nonstructural proteins and to develop in vitro and cell-based 
assays to screen for potential inhibitors. Since drugs targeted 
against proteases, helicases and replicases are already in 
clinical use, structure-based modeling can be employed to 
search existing databases (Chong and Sullivan 2007). 
7.5 Research on better disease management
Hepatitis E is a self-limiting disease that attracts little active 
management in endemic areas. Thus, fulminant cases are 
poorly managed and have high rates of mortality. Since 
the host response is believed to determine the progression 
and outcome of hepatitis E, it makes sense to characterize 
biomarkers of disease progression. Research on the 
discovery and validation of biomarkers in the plasma and 
urine of hepatitis E patients and their association with 
disease severity would be important. Such surrogate markers 
might lead to tests that could identify patients with increased 
susceptibility to develop severe disease. Once identifi ed, 
these patients can be clinically managed and this would 
reduce mortality. 
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